β-amyloid oligomers and prion protein: Fatal attraction?

Prion

Volumn 5, Issue 1, 2011, Pages 10-15

  Forloni, Gianluigi ^a   Balducci, Claudia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alzheimer disease; Protein misfolding; Synaptopathology; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; OLIGOMER; PRION PROTEIN;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN DISEASE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HUMAN; KNOCKOUT MOUSE; LONG TERM POTENTIATION; MEMORY; MEMORY DISORDER; MOUSE; NERVE CELL; NEUROBLASTOMA CELL; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; NOTE; PATHOGENESIS; PRION DISEASE; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; LONG-TERM POTENTIATION; MICE; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PRIONS; PRPC PROTEINS;

MUS; MUS MUSCULUS;

EID: 78651410464     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.5.1.14367     Document Type: Note

References (65)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362:329-44.
2. Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet 2004; 363:51-61.
3. Mastrianni JA, Brown K. The prion diseases. J Geriatr Psychiatry Neurol 2010;23:277-98.
4. DeArmond SJ, Prusiner SB. Perspectives on prion biology, prion disease pathogenesis and pharmacologic approaches to treatment. Clin Lab Med 2003; 23:1-41.
5. Del Bo R, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, Galimberti G, et al. Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging 2006; 27:770.
6. Gacia M, Safranow K, Styczynska M, Jakubowska K, Pepłonska B, Chodakowska-Zebrowska M, et al. Prion protein gene M129 allele is a risk factor for Alzheimer's disease. J Neural Transm 2006; 113:1747-51.
7. Giannattasio C, Poleggi A, Puopolo M, Pocchiari M, Antuono P, Dal Forno G, et al. Survival in Alzheimer's disease is shorter in women carrying heterozygosity at codon 129 of the PRNP gene and no APOE epsilon 4 allele. Dement Geriatr Cogn Disord 2008; 25:354-8.
8. Kellett KA, Hooper NM. Prion protein and Alzheimer disease. Prion 2009; 3:190-4.
9. Vincent B, Sunyach C, Orzechowski HD, St. George-Hyslop P, Checler F. p53-dependent transcriptional control of cellular prion by presenilins. J Neurosci 2009; 29:6752-60.
10. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, et al. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med 2010; 2:306-14.
11. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, et al. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci 2010; 30:4528-35.
12. Jean L, Thomas B, Tahiri-Alaoui A, Shaw M, Vaux DJ. Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease. PLoS ONE 2007; 2:652.
13. Vishveshwara N, Liebman SW. Heterologous cross-seeding mimics cross-species prion conversion in a yeast model. BMC Biol 2009; 7:26.
14. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457:1128-32.
15. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 1994; 91:12243-7.
16. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 1995; 64:253-65.
17. Forloni G, Lucca E, Angeretti N, Della Torre P, Salmona M. Amidation of beta-amyloid peptide strongly reduced the amyloidogenic activity without alteration of the neurotoxicity. J Neurochem 1997; 69:2048-54.
18. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007; 101:1172-84.
19. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155:853-86.
20. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46:860-86.
21. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283:1571-8. (Pubitemid 30161512)
22. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95:6448-53.
23. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14:837-42.
24. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ, Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006; 572:477-92.
25. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002; 924:133-40.
26. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999; 96:3228-33. (Pubitemid 29148873)
27. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000; 20:4050-8. (Pubitemid 30365675)
28. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8:79-84.
29. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440:352-7.
30. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco P, et al. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003; 42:12749-60.
31. Klein WL, Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002; 41:345-52.
32. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 2010; 107:2295-300.
33. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron 2010; 66:631-45.
34. Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, et al. N Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 2006; 281:17941-5. (Pubitemid 44035593)
35. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27:2866-75. (Pubitemid 46438992)
36. Collingridge GL, Isaac JT, Wang YT. Receptor trafficking and synaptic plasticity. Nat Rev Neurosci 2004; 5:952-62.
37. Luscher C, Nicoll RA, Malenka RC, Muller D. Synaptic plasticity and dynamic modulation of the postsynaptic membrane. Nat Neurosci 2000; 3:545-50. (Pubitemid 30332072)
38. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006; 52:831-43. (Pubitemid 44828454)
39. Balducci C, Tonini R, Zianni E, Nazzaro C, Fiordaliso F, Salio M, et al. Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in APP23 transgenic mice. J Alzheimers Dis 2010; 21:1367-81. DOI: 10.3233/JAD-2010-100675
40. Fioriti L, Quaglio E, Massignan T, Colombo L, Stewart RS, Salmona M, et al. The neurotoxicity of prion protein (PrP)peptide 106-126 is independent of the expression level of PrP and is not mediated by abnormal PrP species. Mol Cell Neurosci 2005; 28:165-76. (Pubitemid 39656020)
41. Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role of N-terminal residues. J Biol Chem 2010; 285:26377-83.
42. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laurén J, Gimbel ZA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 2010; 30:6367-74.
43. C monoclonal antibody infusion as a novel treatment for cognitive deficits in an alzheimer's disease model mouse. BMC Neurosci 2010; 11:130.
44. Kessels HW, Nguyen LN, Nabavi S, Malinow R. The prion protein as a receptor for amyloid-beta. Nature 2010; 466:3-4.
45. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Reply. Nature 2010; 466:4-5.
46. C a mediator of Aâ toxicity in Alzheimer's disease? J Neurosci 2010; 30:11883-4.
47. Lord A, Englund H, Söderberg L, Tucker S, Clausen F, Hillered L, et al. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J 2009; 276:995-1006.
48. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010; 66:739-54.
49. Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, Schoemaker H, et al. Amyloid beta oligomers (Abeta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci 2008; 28:788-97. (Pubitemid 351159014)
50. Abdalla S, Lother H, el Missiry A, Langer A, Sergeev P, el Faramawy Y, et al. Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J Biol Chem 2009; 284:6554-65.
51. Dougherty JJ, Wu J, Nichols RA. Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci 2003; 23:6740-7. (Pubitemid 36951200)
52. Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 2009; 29:918-29.
53. Decker H, Jürgensen S, Adrover MF, Brito-Moreira J, Bomfim TR, Klein WL, et al. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic Aβ oligomers. J Neurochem 2010; 115:1520-9.
54. Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 2006; 26:6011-8. (Pubitemid 44318367)
55. Stefani M. Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. FEBS J 2010; 277:4602-13.
56. Sepulveda FJ, Parodi J, Peoples RW, Opazo C, Aguayo LG. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One 2010; 5:11820.
57. Kawahara M. Neurotoxicity of amyloid protein: oligomerization, channel formation and calcium dyshomeostasis. Curr Pharm Des 2010; 16:2779-89.
58. Diaz JC, Simakova O, Jacobson KA, Arispe N, Pollard HB. Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from A beta cytotoxicity. Proc Natl Acad Sci USA 2009; 106:3348-53.
59. Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid β-protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 1993; 90:567-71. (Pubitemid 23028904)
60. Kourie JI, Kenna BL, Tew D, Jobling MF, Curtain CC, Masters CL, et al. Copper modulation of ion channels of PrP[106-126] mutant prion peptide fragments. J Membr Biol 2003; 193:35-45.
61. Bahadi R, Farrelly PV, Kenna BL, Kourie JI, Tagliavini F, Forloni G, et al. Channels formed with a mutant prion protein PrP(82-146) homologous to a 7 kDa fragment in diseased brain of GSS patients. Am J Physiol Cell Physiol 2003; 285:862-72.
62. Strodel B, Lee JW, Whittleston CS, Wales DJ. Transmembrane structures for Alzheimer's Aβ(1-42) oligomers. Am Chem Soc 2010; 132:13300-12.
63. Malchiodi-Albedi F, Contrusciere V, Raggi C, Fecchi K, Rainaldi G, Paradisi S, et al. Lipid raft disruption protects mature neurons against amyloid oligomer toxicity. Biochim Biophys Acta 2010; 1802:406-15.
64. Manzoni C, Colombo L, Messa M, Cagnotto A, Balducci C, Forloni G, et al. Membrane proteins and Aβ peptide toxicity. Alzheimers Dement 2009; 5:490-1.
65. Galindo MF, Ikuta I, Zhu X, Casadesus G, Jordán J. Mitochondrial biology in Alzheimer's disease pathogenesis. J Neurochem 2010; 114:933-45.